Novartis announces phase III study of Jakavi in chronic graft-versus-host disease met primary and key secondary endpoints

This article was originally published here

The study also met key secondary endpoints, significantly improving failure-free survival and patient-reported symptoms assessed by a validated chronic GvHD-specific score. These topline results build on positive data

The post Novartis announces phase III study of Jakavi in chronic graft-versus-host disease met primary and key secondary endpoints appeared first on Pharmaceutical Business review.

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply